Reports Q4 revenue $805M, consensus $794.8M. “Our strong finish to 2025 was a result of the team’s relentless execution of our growth strategy,” said Eric Green, West’s President, Chief Executive Officer and Chair of the Board. “Our performance in the quarter was led by our High-Value Product Components business in our Proprietary Products Segment, enabling us to deliver double-digit adjusted earnings per share growth. We expect positive momentum to continue in 2026, which will be a key year of execution and operational excellence to drive sustainable growth and create value for our patients, customers and shareholders.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical price target lowered to $295 from $365 at Jefferies
- WST Earnings this Week: How Will it Perform?
- West Pharmaceutical price target lowered to $320 from $390 at Evercore ISI
- West Pharmaceutical Services: GLP-1 Dependency, Emerging Oral-Formulation Risks, and Insufficient Diversification Justify Hold Rating
- West Pharmaceutical: SmartDose Divestiture Clarifies Strategy and Enhances Margin Outlook, Supporting Buy Rating